Summary
AbbVie Inc. reported strong performance for the nine months ended September 29, 2019, with net revenues reaching $24.6 billion, a 0.5% increase year-over-year on an actual currency basis, and 1.8% on a constant currency basis. Operating earnings were $9.0 billion, and diluted earnings per share (EPS) stood at $3.41. The company generated robust operating cash flow of $10.0 billion. The most significant strategic development highlighted is the pending acquisition of Allergan plc, announced in June 2019, valued at approximately $63 billion. This transaction is expected to close in early 2020 and is subject to regulatory approvals. AbbVie also continued to invest heavily in its R&D pipeline, focusing on immunology, oncology, and neuroscience, with new product launches like SKYRIZI and RINVOQ showing initial revenue contributions. Despite facing biosimilar competition for HUMIRA internationally, the company saw strong growth in key products such as IMBRUVICA and VENCLEXTA.
Financial Highlights
54 data points| Revenue | $8.48B |
| Cost of Revenue | $1.92B |
| Gross Profit | $6.56B |
| SG&A Expenses | $1.66B |
| Operating Expenses | $5.86B |
| Operating Income | $2.62B |
| Interest Expense | $480.00M |
| Net Income | $1.88B |
| EPS (Basic) | $1.27 |
| EPS (Diluted) | $1.26 |
| Shares Outstanding (Basic) | 1.48B |
| Shares Outstanding (Diluted) | 1.48B |
Key Highlights
- 1AbbVie reported net revenues of $24.6 billion for the first nine months of 2019, a slight increase driven by products like IMBRUVICA and VENCLEXTA, as well as new immunology launches, partially offset by international HUMIRA biosimilar competition.
- 2The company announced a major pending acquisition of Allergan plc for approximately $63 billion, expected to close in early 2020, subject to regulatory approvals.
- 3Diluted Earnings Per Share (EPS) was $3.41 for the nine months ended September 30, 2019.
- 4Research and Development (R&D) expenses increased significantly to $4.86 billion for the nine months ended September 30, 2019, including a substantial $1.0 billion intangible asset impairment charge related to the termination of the Rova-T program.
- 5The company's balance sheet shows total assets of $59.4 billion and total liabilities of $59.4 billion as of September 30, 2019. Notably, total stockholders' equity was negative ($8.2 billion), largely due to significant treasury stock repurchases and accumulated other comprehensive loss.
- 6AbbVie continued its commitment to returning capital to shareholders, declaring an increased quarterly cash dividend of $1.18 per share for 2020 and repurchasing $300 million of its stock in the first nine months of 2019.
- 7New immunology products, SKYRIZI and RINVOQ, launched in 2019, generated initial revenues of $139 million and $14 million, respectively, for the nine-month period.